Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy
Authors
Higano, C. S.Harshman, L. C.
Dizdarevic, S.
Logue, John P
Richardson, T.
George, S.
Song, D.
de Jong, I. J.
Tomaszewski, J.
Saad, F.
Miller, K.
Meltzer, J.
Sandstrom, P.
Tombal, B. F.
Sartor, A. O.
Affiliation
Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WAIssue Date
2020